Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA

Executive Summary

A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs. 

You may also be interested in...



Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda

US FDA plans new guidances on real-world data, clinical trial statistics, and patient input in coming this year.

Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update

Update of 2007 guidance includes discussion on use of newer endpoints and clarifies that oncology endpoints can serve different purposes.

Peter Stein Takes Short Path To Director Of US FDA Drug Office

An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel